A review in the journal Drugs found that moving to a biosimilar from a reference drug “is not inherently dangerous, and that patients, healthcare professionals, and the public should not assume that it is problematic.” Researchers looked at data from 90 studies, finding no differences in safety or efficacy after numerous switches between the biologic and the biosimilar.

Click Here to view the original article at Regulatory Affairs Professional Society